$INCY
INCYTE CORP Stock $incy

$incy Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-Q Financial Statement

#000110465913036617 Filed on May 02, 2013

Income Statement

Concept	2013 Q1	2012 Q1
Revenue	$71.08M	$36.18M
YoY Change	96.46%	13.15%
Cost Of Revenue	$150.0K	$11.00K
YoY Change	1263.64%
Gross Profit	$70.93M	$36.17M
YoY Change	96.1%	13.03%
Gross Profit Margin	99.79%	99.97%
Selling, General & Admin	$22.26M	$21.40M
YoY Change	4.04%	98.11%
% of Gross Profit	31.39%	59.16%
Research & Development	$52.76M	$48.96M
YoY Change	7.77%	34.88%
% of Gross Profit	74.39%	135.37%
Depreciation & Amortization	$7.734M	$7.234M
YoY Change	6.91%	13.03%
% of Gross Profit	10.9%	20.0%
Operating Expenses	$75.02M	$70.36M
YoY Change	6.63%	49.38%
Operating Profit	-$4.097M	-$34.19M
YoY Change	-88.02%	126.41%
Interest Expense	$11.73M	$11.29M
YoY Change	3.88%	-205.51%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$15.63M	-$45.43M
YoY Change	-65.6%	71.42%
Income Tax	$43.00K	$0.00
% Of Pretax Income
Net Earnings	-$15.70M	-$45.40M
YoY Change	-65.42%	71.32%
Net Earnings / Revenue	-22.09%	-125.49%
Basic Earnings Per Share		-$0.36
Diluted Earnings Per Share	-$116.9K	-$0.36
COMMON SHARES
Basic Shares Outstanding	133.9M shares	127.2M shares
Diluted Shares Outstanding		127.2M shares

Balance Sheet

Concept	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$270.2M	$236.4M
YoY Change	14.3%	-38.37%
Cash & Equivalents	$265.8M	$231.9M
Short-Term Investments	$4.400M	$4.600M
Other Short-Term Assets	$10.70M	$26.70M
YoY Change	-59.93%	3.49%
Inventory	$189.0K
Prepaid Expenses
Receivables	$28.00M	$13.00M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$309.1M	$276.2M
YoY Change	11.92%	-35.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.485M	$6.200M
YoY Change	4.6%	26.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$9.100M	$3.500M
YoY Change	160.0%	-81.48%
Total Long-Term Assets	$21.17M	$17.40M
YoY Change	21.66%	-48.21%
TOTAL ASSETS
Total Short-Term Assets	$309.1M	$276.2M
Total Long-Term Assets	$21.17M	$17.40M
Total Assets	$330.3M	$293.6M
YoY Change	12.49%	-36.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.52M	$13.20M
YoY Change	17.54%	69.23%
Accrued Expenses	$31.88M	$46.60M
YoY Change	-31.59%	31.64%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$9.500M
YoY Change	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$121.3M	$142.3M
YoY Change	-14.77%	29.13%
LONG-TERM LIABILITIES
Long-Term Debt	$337.5M	$312.6M
YoY Change	7.97%	4.58%
Other Long-Term Liabilities	$35.00M	$87.50M
YoY Change	-60.0%	-43.37%
Total Long-Term Liabilities	$372.5M	$400.1M
YoY Change	-6.9%	-11.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$121.3M	$142.3M
Total Long-Term Liabilities	$372.5M	$400.1M
Total Liabilities	$493.8M	$542.5M
YoY Change	-8.98%	-3.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.670B
YoY Change
Common Stock	$1.504B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$163.5M	-$248.9M
YoY Change
Total Liabilities & Shareholders Equity	$330.3M	$293.6M
YoY Change	12.49%	-36.12%

Cashflow Statement

Concept	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$15.70M	-$45.40M
YoY Change	-65.42%	71.32%
Depreciation, Depletion And Amortization	$7.734M	$7.234M
YoY Change	6.91%	13.03%
Cash From Operating Activities	$24.70M	-$54.40M
YoY Change	-145.4%	23.08%
INVESTING ACTIVITIES
Capital Expenditures	-$900.0K	-$500.0K
YoY Change	80.0%	-16.67%
Acquisitions
YoY Change
Other Investing Activities	$100.0K	$200.0K
YoY Change	-50.0%	-66.67%
Cash From Investing Activities	-$800.0K	-$300.0K
YoY Change	166.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	17.80M	13.40M
YoY Change	32.84%	226.83%
NET CHANGE
Cash From Operating Activities	24.70M	-54.40M
Cash From Investing Activities	-800.0K	-300.0K
Cash From Financing Activities	17.80M	13.40M
Net Change In Cash	41.70M	-41.30M
YoY Change	-200.97%	2.99%
FREE CASH FLOW
Cash From Operating Activities	$24.70M	-$54.40M
Capital Expenditures	-$900.0K	-$500.0K
Free Cash Flow	$25.60M	-$53.90M
YoY Change	-147.5%	23.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2366000	USD
CY2013Q1	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1999000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1878000	USD
CY2013Q1	incy	Percentage Of Medi Care Part D Insurance Coverage Gap Required To Be Funded By Manufacturers PercentageOfMediCarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers	0.50	pure
CY2013Q1	incy	Inventory Finished Goods Useful Life Minimum InventoryFinishedGoodsUsefulLifeMinimum	P24M
CY2013Q1	incy	Inventory Finished Goods Useful Life Maximum InventoryFinishedGoodsUsefulLifeMaximum	P36M
CY2013Q1	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	4365000	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	591000	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7884000	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	278000	USD
CY2012Q4	incy	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	8753000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	278000	USD
CY2012Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	8475000	USD
CY2013Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	591000	USD
CY2013Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8550000	USD
CY2013Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	189000	USD
CY2013Q1	incy	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	9330000	USD
CY2013Q1	us-gaap	Inventory Net InventoryNet	189000	USD
CY2013Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	9141000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2483000	USD
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	4361000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9200000	USD
CY2012Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9900000	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed	Black-Scholes valuation model
CY2013Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4365000	USD
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	70818118	shares
CY2012Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	72800409	shares
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	INCYTE CORP
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000879169
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012Q1	us-gaap	Contracts Revenue ContractsRevenue	16737000	USD
CY2012Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	163000	USD
CY2012Q1	us-gaap	Revenues Revenues	36179000	USD
CY2012Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	11000	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48960000	USD
CY2012Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21396000	USD
CY2012Q1	us-gaap	Costs And Expenses CostsAndExpenses	70367000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-34188000	USD
CY2013Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	135749206	shares
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	us-gaap	Assets Current AssetsCurrent	309113000	USD
CY2013Q1	us-gaap	Assets Assets	330282000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	121283000	USD
CY2013Q1	us-gaap	Liabilities Liabilities	493808000	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	-163526000	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	330282000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	224057000	USD
CY2012Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4361000	USD
CY2012Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	70951000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9867000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	309514000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6348000	USD
CY2012Q4	incy	Intangible And Other Assets Net IntangibleAndOtherAssetsNet	6082000	USD
CY2012Q4	us-gaap	Assets Assets	330419000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13961000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22899000	USD
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4750000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28385000	USD
CY2012Q4	incy	Deferred Collaborative Agreements Revenue Current DeferredCollaborativeAgreementsRevenueCurrent	66079000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	136074000	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	136000	USD
CY2012Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	322043000	USD
CY2012Q4	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	9033000	USD
CY2012Q4	incy	Deferred Collaborative Agreements Revenue Noncurrent DeferredCollaborativeAgreementsRevenueNoncurrent	38226000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	505376000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	133000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1476922000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1878000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1653890000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-174957000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	330419000	USD
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	133462185	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	133462185	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135529786	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135529786	shares
CY2012Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	19279000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-54401000	USD
CY2012Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	496000	USD
CY2012Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	167000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-329000	USD
CY2012Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	13421000	USD
CY2012Q1	us-gaap	Investment Income Net InvestmentIncomeNet	52000	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	11290000	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-45426000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45426000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	127203000	shares
CY2013Q1	us-gaap	Revenues Revenues	71077000	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	75174000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4097000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15626000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15669000	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43000	USD
CY2013Q1	us-gaap	Royalty Revenue RoyaltyRevenue	5909000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	293000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	293000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45133000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	136000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	121000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15548000	USD
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7234000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9932000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6595000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-29000	USD
CY2012Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-23000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1765000	USD
CY2012Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4776000	USD
CY2012Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3673000	USD
CY2012Q1	incy	Increase Decrease Deferred Revenue Collaborative Agreements IncreaseDecreaseDeferredRevenueCollaborativeAgreements	-16730000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	13421000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-41309000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	24738000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-758000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17777000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	41757000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	273164000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	231855000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	265814000	USD
CY2013Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">1.     Organization and business</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Incyte Corporation (“Incyte,” “we,” “us,” or “our”) is a biopharmaceutical company focused on developing and commercializing proprietary small molecule drugs for oncology and inflammation. Our pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> (ruxolitinib).</font></p> </div>
CY2013Q1	incy	Deferred Collaborative Agreements Revenue Current DeferredCollaborativeAgreementsRevenueCurrent	52554000	USD
CY2013Q1	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	2	item
CY2013Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	328354000	USD
CY2013Q1	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	9159000	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	28041000	USD
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10704000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6485000	USD
CY2013Q1	incy	Intangible And Other Assets Net IntangibleAndOtherAssetsNet	5543000	USD
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	15515000	USD
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11836000	USD
CY2013Q1	us-gaap	Interest Payable Current InterestPayableCurrent	9500000	USD
CY2013Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31878000	USD
CY2013Q2	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	2	item
CY2013Q1	incy	Deferred Collaborative Agreements Revenue Noncurrent DeferredCollaborativeAgreementsRevenueNoncurrent	35012000	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1503898000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1999000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1669559000	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	48289000	USD
CY2013Q1	us-gaap	Contracts Revenue ContractsRevenue	16737000	USD
CY2013Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	142000	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	150000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52763000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22261000	USD
CY2013Q1	us-gaap	Investment Income Net InvestmentIncomeNet	199000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	11728000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	134345000	shares
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-42910000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	837000	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	577000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1554000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2820000	USD
CY2013Q1	incy	Increase Decrease Deferred Revenue Collaborative Agreements IncreaseDecreaseDeferredRevenueCollaborativeAgreements	-16739000	USD
CY2013Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	894000	USD
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	136000	USD
CY2013Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	17777000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7734000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9197000	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	15000	USD

Files In Submission

Name	View Source	Status
0001104659-13-036617-index-headers.html	Edgar Link	pending
0001104659-13-036617-index.html	Edgar Link	pending
0001104659-13-036617.txt	Edgar Link	pending
0001104659-13-036617-xbrl.zip	Edgar Link	pending
a13-8416_110q.htm	Edgar Link	pending
a13-8416_1ex31d1.htm	Edgar Link	pending
a13-8416_1ex31d2.htm	Edgar Link	pending
a13-8416_1ex32d1.htm	Edgar Link	pending
a13-8416_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
incy-20130331.xml	Edgar Link	completed
incy-20130331.xsd	Edgar Link	pending
incy-20130331_cal.xml	Edgar Link	unprocessable
incy-20130331_def.xml	Edgar Link	unprocessable
incy-20130331_lab.xml	Edgar Link	unprocessable
incy-20130331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INCY
INCYTE CORP Stock $incy

2013 Q1 Form 10-Q Financial Statement

#000110465913036617 Filed on May 02, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INCY INCYTE CORP Stock $incy

2013 Q1 Form 10-Q Financial Statement

#000110465913036617 Filed on May 02, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INCY
INCYTE CORP Stock $incy